Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shreyaskumar Patel

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse OutcomesRyan A Denu, Richard K Yang, Alexander J Lazar, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Cancer Medicine|September 24, 2022
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcomaPrapassorn Thirasastr, Heather Lin, Behrang Amini, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2023
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse OutcomesRyan A Denu, Richard K Yang, Alexander J Lazar, et al.
Oncotarget|September 3, 2016
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancyHaeseong Park, Ignacio Garrido-Laguna, Aung Naing, et al.
Cancer Medicine|September 24, 2022
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcomaPrapassorn Thirasastr, Heather Lin, Behrang Amini, et al.
JAMA Oncology|May 1, 2018
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to ImatinibScott M Schuetze, Vanessa Bolejack, Dafydd G Thomas, et al.
Journal of Hematology & Oncology|June 12, 2015
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusionVivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
The Oncologist|July 30, 2017
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part SarcomaSilvia Stacchiotti, Olivier Mir, Axel Le Cesne, et al.
Cancers|May 11, 2024
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center ExperienceLewis F Nasr, Marianne Zoghbi, Rossana Lazcano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Pageof 12